Key points from article :
Bit Bio, previously known as Elpis Biotechnology, secured $41.5 million in a Series A funding round.
Aims to commercialize Opti-OX, a proprietary technology platform for the efficient and consistent reprogramming.
Through the Opti-Ox platform, stem cells are reprogrammed in order to take on a new identity.
It is already able to produce human cells at unmatched scale, speed and consistency.
Sparked new hopes for the treatment of cancer.
Bit Bio’s approach aims to tackle limited availability of human cells.
The company’s technology will reduce the need for animal studies.
"Moonshot goal is to develop a platform capable of producing every human cell type," - Kotter, CEO at Bit Bio
“A new generation of cell and tissue therapies for tackling cancer, neurodegenerative disorders and autoimmune diseases," - Kotter.
"Support of investors will catalyze this unique convergence of biology and engineering,” - Kotter.
